Illumina (ILMN) is continually garnering investors' attention, marked by multiple share acquisitions by various investing firms and advisories, such as
Claro Advisors and
Swedbank AB, further reinforcing positive sentiment amongst investors.
HSBC has upgraded its rating to
Strong-Buy, and Barclays has raised its price target for the stock, suggesting strong analyst consensus. Recently, Illumina announced the launch of
compact, low-cost gene sequencing devices, expanding their product portfolio. These activities have resulted in the stock hitting a new 1-year high. The
single-cell analysis and discovery sector may see accelerated growth with Illumina's acquisition of
Fluent BioSciences. Illumina's Board of Directors has approved a
spin-off of Grail shares, which could magnetize more investor interest. A recent legal win in the European court over Illumina's Grail saga and seemingly higher endorsement from
Barclays and
HSBC might be the reasons behind the bull wave forming for ILMN. However, Illumina's reduced 2024 sales outlook and the recent take of a significant goodwill impairment charge related to Grail could dampen investor sentiment.
Illumina ILMN News Analytics from Thu, 08 Feb 2024 08:00:00 GMT to Sat, 19 Oct 2024 09:57:56 GMT -
Rating 8
- Innovation 7
- Rumor -2
